Phio Pharmaceuticals Corp Stock Cash And Equivalents
| PHIO Stock | USD 2.53 0.15 6.30% |
Phio Pharmaceuticals Corp fundamentals help investors to digest information that contributes to Phio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Phio Stock. The fundamental analysis module provides a way to measure Phio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Phio Pharmaceuticals stock.
Phio | Cash And Equivalents |
Phio Pharmaceuticals Corp Company Cash And Equivalents Analysis
Phio Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Phio Pharmaceuticals Cash And Equivalents | 18.02 M |
Most of Phio Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phio Pharmaceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Phio Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Phio Pharmaceuticals is extremely important. It helps to project a fair market value of Phio Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Phio Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Phio Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Phio Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Phio Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Phio Pharmaceuticals Corp has 18.02 M in Cash And Equivalents. This is 97.8% lower than that of the Biotechnology sector and 95.97% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 99.33% higher than that of the company.
Phio Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phio Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phio Pharmaceuticals by comparing valuation metrics of similar companies.Phio Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Phio Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Phio Pharmaceuticals from analyzing Phio Pharmaceuticals' financial statements. These drivers represent accounts that assess Phio Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Phio Pharmaceuticals' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 2.3M | 4.3M | 12.3M | 5.1M | 5.8M | 5.5M | |
| Enterprise Value | (12.6M) | (2.1M) | (1.3M) | (6.4M) | (7.4M) | (7.0M) |
Phio Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Phio Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Phio Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Phio Fundamentals
| Return On Equity | -1.27 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | (5.94 M) | ||||
| Shares Outstanding | 860.72 K | ||||
| Shares Owned By Insiders | 5.89 % | ||||
| Shares Owned By Institutions | 2.07 % | ||||
| Number Of Shares Shorted | 51.49 K | ||||
| Price To Earning | (0.80) X | ||||
| Price To Book | 0.51 X | ||||
| Price To Sales | 48.01 X | ||||
| Gross Profit | (7.01 M) | ||||
| EBITDA | (10.64 M) | ||||
| Net Income | (10.83 M) | ||||
| Cash And Equivalents | 18.02 M | ||||
| Cash Per Share | 1.32 X | ||||
| Total Debt | 35 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 7.39 X | ||||
| Cash Flow From Operations | (10.75 M) | ||||
| Short Ratio | 0.50 X | ||||
| Earnings Per Share | (14.81) X | ||||
| Target Price | 36.0 | ||||
| Beta | 1.47 | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 9.36 M | ||||
| Retained Earnings | (139.21 M) | ||||
| Working Capital | 7.69 M | ||||
| Current Asset | 9.23 M | ||||
| Current Liabilities | 2.17 M | ||||
| Net Asset | 9.36 M |
About Phio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phio Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phio Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Phio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Phio Stock
The ability to find closely correlated positions to Phio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phio Pharmaceuticals Corp to buy it.
The correlation of Phio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phio Pharmaceuticals Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Phio Pharmaceuticals Piotroski F Score and Phio Pharmaceuticals Altman Z Score analysis. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phio Pharmaceuticals. If investors know Phio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.81) | Return On Assets (0.61) | Return On Equity (1.27) |
The market value of Phio Pharmaceuticals Corp is measured differently than its book value, which is the value of Phio that is recorded on the company's balance sheet. Investors also form their own opinion of Phio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.